Phase ii trial of sorafenib in combination with capecitabine in patients with hepatocellular Carcinoma: INST 08-20

Oncologist

Volumn 22, Issue 10, 2017, Pages

  Patt, Yehuda ^a   Rojas Hernandez, Cristhiam ^b   Fekrazad, Houman Mohammad ^c   Bansal, Pranshu ^a   Lee, Fa Chyi ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; CAPECITABINE; HEMOGLOBIN; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ACNE; ADULT; ALOPECIA; ANEMIA; ARTICLE; CANCER STAGING; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DISEASE CONTROL; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MORTALITY; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; ORAL MUCOSITIS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTOPENIA; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; LIVER TUMOR; PATHOLOGY; PHASE 2 CLINICAL TRIAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CAPECITABINE; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 85034036598     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2017-0168     Document Type: Article

References (12)

1. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
2. Lencioni R, Kudo M, Ye SL et al. First interimanalysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. Int J Clin Pract 2012;66:675-683.
3. Patt YZ, Hassan MM, Aguayo A et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004;101:578-586.
4. Lee JO, Lee KW, Oh DY et al. Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol 2009;20:1402-1407.
5. Shim JH, Park JW, Nam BH et al. Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 2009;63: 459-467.
6. Hsu CH, Yang TS, Hsu C et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 2010;102:981-986.
7. Yau T, Chan P, Ng KK et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: Presence of lung metastasis predicts poor response. Cancer 2009;115:428-436.
8. Benson AB, Abrams TA, Ben-Josef E et al. NCCN clinical practice guidelines in oncology: Hepatobiliary cancers. J Natl Compr Canc Netw 2009;7:350-391.
9. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-773.
10. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-4300.
11. Furuse J, Ishii H, Nakachi K et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008;99: 159-165.
12. Ozenne V, Paradis V, Pernot S et al. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 2010;22:1106-1110.